Eastern Bank Grows Position in Boston Scientific Corporation $BSX

Eastern Bank lifted its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 9.2% in the 3rd quarter, Holdings Channel reports. The firm owned 293,178 shares of the medical equipment provider’s stock after acquiring an additional 24,600 shares during the period. Eastern Bank’s holdings in Boston Scientific were worth $28,623,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Brighton Jones LLC grew its stake in Boston Scientific by 0.8% in the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after buying an additional 226 shares in the last quarter. Geneos Wealth Management Inc. lifted its holdings in shares of Boston Scientific by 136.7% during the 1st quarter. Geneos Wealth Management Inc. now owns 3,423 shares of the medical equipment provider’s stock worth $345,000 after acquiring an additional 1,977 shares during the last quarter. Modern Wealth Management LLC grew its position in Boston Scientific by 7.9% in the first quarter. Modern Wealth Management LLC now owns 2,974 shares of the medical equipment provider’s stock worth $300,000 after acquiring an additional 218 shares in the last quarter. Parallel Advisors LLC increased its stake in Boston Scientific by 5.9% in the second quarter. Parallel Advisors LLC now owns 16,370 shares of the medical equipment provider’s stock valued at $1,758,000 after acquiring an additional 911 shares during the last quarter. Finally, NBC Securities Inc. increased its stake in Boston Scientific by 3.9% in the second quarter. NBC Securities Inc. now owns 12,598 shares of the medical equipment provider’s stock valued at $1,353,000 after acquiring an additional 472 shares during the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Stock Down 1.8%

Shares of Boston Scientific stock opened at $94.02 on Wednesday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.96 and a current ratio of 1.51. Boston Scientific Corporation has a 52-week low of $85.98 and a 52-week high of $109.50. The company’s 50 day moving average price is $97.43 and its 200-day moving average price is $100.58. The stock has a market capitalization of $139.37 billion, a price-to-earnings ratio of 50.28, a P/E/G ratio of 1.69 and a beta of 0.67.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.71 by $0.04. The business had revenue of $5.07 billion during the quarter, compared to analysts’ expectations of $4.97 billion. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The firm’s revenue for the quarter was up 20.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.63 EPS. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. Equities research analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current year.

Insider Activity at Boston Scientific

In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company’s stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the completion of the transaction, the executive vice president owned 178,342 shares of the company’s stock, valued at $17,739,678.74. This represents a 21.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $101.55, for a total value of $1,758,135.15. Following the completion of the sale, the executive vice president owned 23,600 shares of the company’s stock, valued at approximately $2,396,580. This trade represents a 42.32% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 93,095 shares of company stock worth $9,305,450 in the last 90 days. Company insiders own 0.50% of the company’s stock.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: FDA clearance for the Farapoint PFA catheter expands BSX’s electrophysiology portfolio and supports procedure-driven recurring revenue; regulatory win should accelerate commercial roll‑out in atrial fibrillation ablation. Article Title
• Positive Sentiment: Agreement to acquire Valencia Technologies broadens BSX’s pelvic/uroLOGY offering for urinary incontinence and overactive bladder — gives exposure to a high-growth segment and supports the company’s stated pelvic-health strategy. (Official release) Article Title
• Positive Sentiment: J.P. Morgan coverage/notes highlight expectations for strong PFA performance in 2026 and beyond, reinforcing growth prospects for BSX’s higher‑margin electrophysiology portfolio. Article Title
• Positive Sentiment: Bank of America (analyst Travis Steed) reaffirmed a Buy rating and a $120 price target, citing strategic pelvic‑health expansion and the Valencia deal as upside drivers. Article Title
• Positive Sentiment: Sector write‑ups note BSX is benefiting from favorable product‑mix shifts toward higher‑margin devices, supporting margin expansion and durable revenue growth. Article Title
• Neutral Sentiment: Management’s JP Morgan conference presentation/transcript provides updated strategic context and reinforcement of guidance, useful for modeling but not a discrete catalyst by itself. Article Title
• Negative Sentiment: Short‑term sell pressure: some coverage noted the stock fell despite a strong market day and higher volume — suggesting profit‑taking, rotation away from richly valued medtech names (BSX’s trailing P/E is elevated) may be weighing on the share price. Article Title

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on BSX. BTIG Research reiterated a “buy” rating and issued a $132.00 price objective on shares of Boston Scientific in a report on Friday, November 21st. Erste Group Bank lowered Boston Scientific from a “buy” rating to a “hold” rating in a research note on Friday, October 3rd. The Goldman Sachs Group reiterated a “buy” rating and set a $112.00 price target on shares of Boston Scientific in a research report on Friday. Barclays boosted their price objective on shares of Boston Scientific from $133.00 to $136.00 and gave the stock an “overweight” rating in a report on Thursday, October 2nd. Finally, Robert W. Baird increased their target price on shares of Boston Scientific from $123.00 to $128.00 and gave the company an “outperform” rating in a report on Wednesday, October 1st. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $125.21.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.